Navigation Links
Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics' Pixantrone PIX301 Pivotal Trial
Date:9/27/2011

SEATTLE, Sept. 28, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that a second independent radiology assessment of response and progression endpoint data from CTI's PIX301 clinical trial of pixantrone confirmed the statistical robustness of the PIX301 efficacy data that was previously submitted by CTI to the U.S. Food and Drug Administration ("FDA") in CTI's new drug application ("NDA") for pixantrone.

This second independent assessment was recommended by the FDA's Office of New Drugs ("OND") as part of CTI's appeal of the Complete Response Letter ("CRL") for the NDA, which CTI received from the FDA's Office of Oncology Drug Products.

"The review conducted by a second independent panel of three radiologists confirmed the statistically and clinically significant results the first independent panel reported for the PIX301 study response and progression endpoints," noted James A. Bianco, M.D., CEO of CTI. "We now have two separate independent response assessment panels reporting significant results for complete response/complete response unconfirmed, overall response rate and progression-free survival at both end of treatment and end of study assessment periods as well as among the histologically confirmed aggressive non-Hodgkin's lymphoma ("NHL") subset of patients. We look forward to sharing these confirmatory results with the Division of Oncology Drug Products ("DODP") in our resubmission of the pixantrone NDA."

The review and the review process was conducted based on the recommendations by OND in order to determine that efficacy had been established by confirming confidence in the endpoint ascertainment and reliability of the primary results.

Based on the results of this second independent assessment panel's review, CTI plans on resubmitting the pixantrone NDA as early as October 2011 for accelerated approval.  The DODP previously confirmed that the review of the NDA would be complet
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
7. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
8. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. ... , the Canadian Medical Association (CMA) voted on ... any plant material, including medicinal cannabis. Bedrocan Cannabis Corp., ... supportive of the CMA motion. The CMA ... particular hazards associated with smoking any plant material, including ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... Research Products: Opportunities, Tools & Technologies" report to ... stem cell research products or you wish to expand ... lucrative this market is. The authors know you want ... effectively to scientists, to generate improved revenues and take ...
(Date:8/22/2014)... Mich. , Aug. 22, 2014  Dr. ... Who with the Diamond Lifetime Achievement Award in the ... as CEO of Cardiovascular Clinical Associates. Dr. ... in managing all major aspects of the business; overseeing ... well as primary coronary intervention. In addition, he is ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... CARLSBAD, Calif., Oct. 18 Excaliard Pharmaceuticals, Inc. ... as Chairman of its Board of Directors. Mr. ... years of experience in successfully developing and commercializing ... field.  Excaliard Pharmaceuticals, Inc. is a biotechnology company ...
... Bend Research Inc. ( www.bendres.com ), a ... announced today it has extended its drug discovery ... Company ( www.bms.com ) (NYSE: BMY ... Under the terms of the 3-year agreement, Bristol-Myers ...
Cached Medicine Technology:Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board 2Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb 2
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Many Americans know little ... the possibility of an outbreak in the United States, a ... they are worried that there will be a major Ebola ... they or an immediate family member will get sick with ... latest Harvard School of Public Health poll. However, those ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... Millennium Treatment Group, a drug ... recently launched a new website. Patients, parents, loved ... now find Millennium Treatment Group at http://www.millenniumtreatmentgroup.com ... at the beginning of July. Everything anyone would ... found on the website. There’s an About Us ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... by Kevin Richardson to restore his own vision from legally ... Shane Michaels, prompting an investigative review. , “There is ... glasses or contacts for everyday function, and most people just ... resort to corrective eye surgery that can be pretty risky ...
(Date:8/22/2014)... Beat Eczema , Susan Clark’s best-selling ... methods to completely cure the eczema symptoms they have ... Michaels, prompting an investigative review. , “Although eczema ... can still be extremely debilitating and life-altering for those ... and pain that it causes on the skin can ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Millennium Treatment Group Has a New Website 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2
... night, Oklahoma Governor Brad Henry vetoed Oklahoma House Bill ... business to conduct research that would kill a human ... risk of death or injury. The Oklahoma House ... Senate failed to follow suit.The bill would have banned ...
... Washington G-2 Reports releases top-10 trends to watch ... Demand for outpatient diagnostic imaging has never ... increase over the next three years. In fact, ... increase by double digits across all modalities (CT, ...
... can help physicians objectively assess a patient,s breast density ... changes that may suggest cancer, according to a study ... of Maryland School of Medicine, Baltimore, MD. ... estimates mammographic breast density. Results obtained by the computer ...
... (VQ) as an alternative to CT for the diagnosis ... patient exposure, according to a study performed at Albert ... NY. "VQ scanning is a nuclear test which shows ... is a pulmonary embolism, the air can enter normally, ...
... breeding techniques, shed light on human genome , , THURSDAY, April ... researchers in 25 countries has succeeded in sequencing the entire ... implications for understanding the biology of this bovine and related ... said the authors of two reports in the April 24 ...
... USA applauds President Obama,s national call for volunteerism and urges ... their local communities. President Obama recently signed a new ... learn about volunteer and service opportunities. "We need your service ... not going to tell you what your role should be. ...
Cached Medicine News:Health News:Demand for Outpatient Diagnostic Imaging Forecast to Increase by Double Digits Across All Modalities Through 2012 2Health News:New computer algorithm helps physicians determine and monitor breast density 2Health News:Scientists From 25 Countries Sequence Cow Genome 2Health News:Scientists From 25 Countries Sequence Cow Genome 3Health News:YWCA USA Applauds President Obama's National Call for Volunteer Service 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: